AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (6.8 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Full Length Article | Open Access

Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease

Lulin Huanga,b( )Li FangbQian LiubAbolfazl Doostparast TorshizibKai Wangb( )
The Key Laboratory for Human Disease Gene Study of Sichuan Province, Department of Clinical Laboratory, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, PR China
Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Huntington's disease (HD) is caused by a CAG repeat expansion in the huntingtin (HTT) gene. Knock-in mice carrying a CAG repeat-expanded Htt will develop HD phenotypes. Previous studies suggested dysregulated molecular networks in a CAG length genotype- and the age-dependent manner in brain tissues from knock-in mice carrying expanded Htt CAG repeats. Furthermore, a large-scale phenome analysis defined a behavioral signature for HD genotype in knock-in mice carrying expanded Htt CAG repeats. However, an integrated analysis correlating phenotype features with genotypes (CAG repeat expansions) was not conducted previously. In this study, we revealed the landscape of the behavioral features and gene expression correlations based on 445 mRNA samples and 445 microRNA samples, together with behavioral features (396 PhenoCube behaviors and 111 NeuroCube behaviors) in Htt CAG-knock-in mice. We identified 37 behavioral features that were significantly associated with CAG repeat length including the number of steps and hind limb stand duration. The behavioral features were associated with several gene coexpression groups involved in neuronal dysfunctions, which were also supported by the single-cell RNA sequencing data in the striatum and the spatial gene expression in the brain. We also identified 15 chemicals with significant responses for genes with enriched behavioral features, most of them are agonist or antagonist for dopamine receptors and serotonin receptors used for neurology/psychiatry. Our study provides further evidence that abnormal neuronal signal transduction in the striatum plays an important role in causing HD-related phenotypic behaviors and provided rich information for the further pharmacotherapeutic intervention possibility for HD.

References

1

Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.

2

Barker RA, Mason SL. Neurodegenerative disease: mapping the natural history of Huntington disease. Nat Rev Neurol. 2014;10(1):12-13.

3

Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci. 2005;6(12):919-930.

4

Sadri-Vakili G, Cha JH. Mechanisms of disease: histone modifications in Huntington's disease. Nat Clin Pract Neurol. 2006;2(6):330-338.

5

Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci. 2013;14(10):708-721.

6

Langfelder P, Cantle JP, Chatzopoulou D, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci. 2016;19(4):623-633.

7

Gleichgerrcht E, Ibáñez A, Roca M, Torralva T, Manes F. Decision-making cognition in neurodegenerative diseases. Nat Rev Neurol. 2010;6(11):611-623.

8

Alexandrov V, Brunner D, Menalled LB, et al. Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice. Nat Biotechnol. 2016;34(8):838-844.

9

Alexandrov V, Brunner D, Hanania T, Leahy E. High-throughput analysis of behavior for drug discovery. Eur J Pharmacol. 2015;750:82-89.

10

Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

11

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:e559.

12

Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.

13

Huang DW, Sherman BT, Tan Q, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183.

14

Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.

15

Isserlin R, Merico D, Voisin V, Bader GD. Enrichment Map - a Cytoscape app to visualize and explore OMICs pathway enrichment results. F1000Res. 2014;3:141.

16

Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.

17

Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 2008;9(Suppl 1):S4.

18

Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214-W220.

19

Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. GeneMANIA: fast gene network construction and function prediction for Cytoscape. F1000Res. 2014;3:153.

20

Gokce O, Stanley GM, Treutlein B, et al. Cellular taxonomy of the mouse striatum as revealed by single-cell RNA-Seq. Cell Rep. 2016;16(4):1126-1137.

21

Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-1935.

22

Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437-1452.

23

Langfelder P, Horvath S. Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol. 2007;1:54.

24

Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA. Endocannabinoid-specific impairment in synaptic plasticity in striatum of Huntington's disease mouse model. J Neurosci. 2018;38(3):544-554.

25

Rothe T, Deliano M, Wójtowicz AM, et al. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice. Neuroscience. 2015;311:519-538.

26

Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J Neurosci. 2009;29(35):10928-10938.

27

Calabresi P, Centonze D, Pisani A, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol. 1998;43(5):586-597.

28

Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci. 2008;27(11):2803-2820.

29

Thomas EA. Striatal specificity of gene expression dysregulation in Huntington's disease. J Neurosci Res. 2006;84(6):1151-1164.

30

Pchitskaya E, Popugaeva E, Bezprozvanny I. Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. Cell Calcium. 2018;70:87-94.

31

Sharma S, Moon CS, Khogali A, et al. Biomarkers in Parkinson's disease (recent update). Neurochem Int. 2013;63(3):201-229.

32

Murmu RP, Li W, Holtmaat A, Li JY. Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. J Neurosci. 2013;33(32):12997-13009.

33

Bulley SJ, Drew CJ, Morton AJ. Direct visualisation of abnormal dendritic spine morphology in the hippocampus of the R6/2 transgenic mouse model of Huntington's disease. J Huntingtons Dis. 2012;1(2):267-273.

34

Herms J, Dorostkar MM. Dendritic spine pathology in neurodegenerative diseases. Annu Rev Pathol. 2016;11:221-250.

35

Smith R, Brundin P, Li JY. Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol Life Sci. 2005;62(17):1901-1912.

36

Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. Lancet Neurol. 2015;14(11):1135-1142.

37

Khedraki A, Reed EJ, Romer SH, et al. Depressed synaptic transmission and reduced vesicle release sites in Huntington's disease neuromuscular junctions. J Neurosci. 2017;37(34):8077-8091.

38

Labuschagne I, Poudel G, Kordsachia C, et al. Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:11-16.

39

Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology. 1985;35(10):1450-1454.

40

Mirek E, Filip M, Chwala W, et al. Three-dimensional trunk and lower limbs characteristics during gait in patients with Huntington’s disease. Front Neurosci. 2017;11:566.

41

Indersmitten T, Tran CH, Cepeda C, Levine MS. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. J Neurophysiol. 2015;113(7):2953-2966.

42

Fourie C, Kim E, Waldvogel H, et al. Differential changes in postsynaptic density proteins in postmortem Huntington's disease and Parkinson's disease human brains. J Neurodegener Dis. 2014;2014:938530.

43

Holley SM, Joshi PR, Parievsky A, et al. Enhanced GABAergic inputs contribute to functional alterations of cholinergic interneurons in the R6/2 mouse model of Huntington's disease. eNeuro. 2015;2(1):ENEURO.0008-14.2015.

44

Fernández-Nogales M, Santos-Galindo M, Hernández IH, Cabrera JR, Lucas JJ. Faulty splicing and cytoskeleton abnormalities in Huntington's disease. Brain Pathol. 2016;26(6):772-778.

45

Eira J, Silva CS, Sousa MM, Liz MA. The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders. Prog Neurobiol. 2016;141:61-82.

46

Sawa A, Wiegand GW, Cooper J, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999;5(10):1194-1198.

47

Bonelli RM, Niederwieser G, Diez J, Gruber A, Költringer P. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuropharmacol. 2002;25(1):58-60.

48

Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatric Dis Treat. 2009;5:1-4.

49

Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol. 2003;17(4):459-460.

50

Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I. Dantrolene is neuroprotective in Huntington’s disease transgenic mouse model. Mol Neurodegener. 2011;6:81.

51

Nikolaus S, Antke C, Kley K, et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci. 2007;18(6):439-472.

52

Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.

53

Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204-216.

54

Duff K, Paulsen JS, Beglinger LJ, et al. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22(2):196-207.

55

Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA. A review of cognition in Huntington's disease. Front Biosci (Schol Ed).. 2013;5:1-18.

56

Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc. 2001;7(1):33-44.

57

Bilney B, Morris ME, Churchyard A, Chiu E, Georgiou-Karistianis N. Evidence for a disorder of locomotor timing in Huntington's disease. Mov Disord. 2005;20(1):51-57.

58

Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord. 2008;23(7):970-976.

59

Delval A, Krystkowiak P, Blatt JL, et al. Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study. J Neurol. 2006;253(1):73-80.

60

Alexandrov V, Brunner D, Hanania T, Leahy E. Reprint of: highthroughtput analysis of behavior for drug discovery. Eur J Pharmacol. 2015;753:127-134.

Genes & Diseases
Pages 479-493
Cite this article:
Huang L, Fang L, Liu Q, et al. Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease. Genes & Diseases, 2022, 9(2): 479-493. https://doi.org/10.1016/j.gendis.2021.05.004

419

Views

4

Downloads

11

Crossref

10

Web of Science

10

Scopus

0

CSCD

Altmetrics

Received: 21 January 2021
Revised: 13 April 2021
Accepted: 12 May 2021
Published: 09 June 2021
© 2021, Chongqing Medical University. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return